In addition, centrosomal cohesion deficits are observed in two distinct peripheral cell types derived from G2019S-LRRK2 PD patients as compared to healthy controls, and these defects are reverted by different LRRK2 kinase inhibitors, suggesting that the centrosomal cohesion phenotype may serve as a cellular biomarker in peripheral cells from PD patients to evaluate efficacy of LRRK2 kinase inhibitors in clinical settings (Madero-Perez et al., 2018). This evidence concerns the gene LRRK2 and Parkinson disease.